| escitalopram / Generic mfg. |
NCT00051259: Effects of Antidepressants on Sexual Functioning |
|
|
| Completed | 3 | 420 | US | Extended-Release Bupropion Hydrochloride | GlaxoSmithKline | Major Depressive Disorder (MDD) | 06/04 | 06/04 | | |
NCT00051272: Effects Of Antidepressants On Sexual Functioning In Adults |
|
|
| Completed | 3 | 425 | US | Extended-release Bupropion Hydrochloride | GlaxoSmithKline | Major Depressive Disorder (MDD) | 06/04 | 06/04 | | |
NCT00179257: The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram |
|
|
| Completed | 3 | 20 | US | sertraline (Zoloft) | Vanderbilt University, Pfizer | Major Depressive Disorder | | 03/05 | | |
NCT00073411: Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression |
|
|
| Completed | 3 | 675 | US | duloxetine, escitalopram, placebo | Eli Lilly and Company | Depression | | 05/05 | | |
NCT00148447: The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia |
|
|
| Completed | 3 | 40 | RoW | escitalopram | BeerYaakov Mental Health Center, Lundbeck Israel | Schizophrenia | | 09/05 | | |
NCT00109044: Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 540 | US | Escitalopram | Forest Laboratories | Major Depressive Disorder | 05/06 | 05/06 | | |
NCT00108979: Study of Escitalopram in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 240 | US | Escitalopram | Forest Laboratories | Major Depressive Disorder | 07/06 | 07/06 | | |
| Completed | 3 | 468 | US, Canada | SR58611A | Sanofi | Major Depressive Disorder | 01/07 | 05/07 | | |
| Completed | 3 | 476 | US, Canada | SR58611A | Sanofi | Major Depressive Disorder | 01/07 | 01/07 | | |
LIBRA, NCT00252343: Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder |
|
|
| Completed | 3 | 360 | US | SR58611A | Sanofi | Anxiety Disorder | 02/07 | 02/07 | | |
| Completed | 3 | 494 | Canada, Europe, RoW | Quetiapine, Amitriptyline, Bupropion, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine | AstraZeneca | Major Depressive Disorder | | 04/07 | | |
NCT00107120: The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 312 | US | Escitalopram, Lexapro (TM), Placebo | Forest Laboratories | Major Depressive Disorder | 05/07 | | | |
NCT00610506: Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features |
|
|
| Completed | 3 | 15 | US | Escitalopram, Escitalopram (Lexapro) | Duke University, Forest Laboratories | Atypical Depression | 05/07 | 05/07 | | |
| Completed | 3 | 450 | Canada, Europe, RoW | Quetiapine SR, Escitalopram | AstraZeneca | Major Depressive Disorder | | 06/07 | | |
GOLD, NCT00329446: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder |
|
|
| Completed | 3 | 800 | US | Quetiapine Fumarate, Escitalopram oxylate | AstraZeneca | Generalized Anxiety Disorder | | 09/07 | | |
NCT00390650: A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder |
|
|
| Completed | 3 | 366 | US, Canada | Saredutant | Sanofi | Anxiety | 11/07 | 11/07 | | |
NCT00415142 / 2006-003793-94: An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 393 | US, Europe, RoW | saredutant (SR48968), placebo, escitalopram | Sanofi | Depressive Disorder | 02/08 | 02/08 | | |
NCT00406640: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women |
|
|
| Completed | 3 | 595 | US, RoW | Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram | Wyeth is now a wholly owned subsidiary of Pfizer | Depression, Depressive Disorder, Depressive Disorder, Major | 02/08 | 10/08 | | |
| Completed | 3 | 510 | Europe, RoW | SR58611A, escitalopram, placebo | Sanofi | Major Depressive Disorder | 02/08 | 02/08 | | |
NCT00417118 / 2006-003805-19: An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder |
|
|
| Completed | 3 | 365 | Canada, Europe, RoW | Saredutant, Escitalopram, Placebo | Sanofi | Generalized Anxiety | 04/08 | 04/08 | | |
| Completed | 3 | 643 | US, Europe, RoW | saredutant (SR48968), escitalopram, placebo | Sanofi | Major Depressive Disorder | 01/09 | 01/09 | | |
NCT00668525: Escitalopram in Adult Patients With Major Depressive Disorder |
|
|
| Completed | 3 | 877 | US | Escitalopram, Placebo | Forest Laboratories | Major Depressive Disorder | 02/09 | | | |
NCT00296933: Memory Functioning and Antidepressant Treatment |
|
|
| Completed | 3 | 60 | Canada | Escitalopram, Bupropion XL | University Health Network, Toronto, GlaxoSmithKline, H. Lundbeck A/S | Depression, Major Depressive Disorder | | | | |
NCT00887679: Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS |
|
|
| Completed | 3 | 30 | US | Escitalopram | Duke University, Forest Laboratories | Anxiety Disorders, HIV Infections | 09/09 | 09/10 | | |
| Terminated | 3 | 29 | US | Escitalopram, Lexapro (escitalopram), Ramelteon, Rozerem (Ramelteon), Placebo | University of Texas Southwestern Medical Center, Takeda Pharmaceuticals North America, Inc. | Major Depressive Disorder, Insomnia | 05/10 | 05/10 | | |
NCT01401595: Brain Imaging and Treatment Studies of the Night Eating Syndrome |
|
|
| Completed | 3 | 87 | US | escitalopram oxalate, Lexapro | University of Pennsylvania, Forest Laboratories | Night Eating Syndrome | 09/11 | 09/11 | | |
ACES 263, NCT01111565 / 2010-018859-97: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 137 | Europe, Canada, US, RoW | Escitalopram, Aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
ACES 255, NCT01111539 / 2010-018796-21: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 211 | Europe, US, RoW | Escitalopram, Aripiprazole, Blinded capsule | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
ACES 256, NCT01111552 / 2010-018858-12: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) |
|
|
| Terminated | 3 | 237 | Europe, US, RoW | Escitalopram, Aripiprazole, OPC-14597, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
| Terminated | 3 | 173 | NA | Aripiprazole, OPC-14597, Escitalopram | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder (MDD) | 09/11 | 09/11 | | |
2010-023576-10: Comparison of Agomelatine (25 mg/day, adjustement to 50 mg/day) with Escitalopram (10mg/day, adjustement to 20 mg/day) on general interest in outpatients with Major Depressive Disorder over 12 weeks of treatment |
|
|
| Completed | 3 | 300 | Europe | S20098, S20098, Film-coated tablet, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, ADIR | Major Depressive Disorder, Depression - Psychiatry, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT01364649: Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction |
|
|
| Completed | 3 | 447 | US, Canada | Vortioxetine, Lu AA21004, Escitalopram, Lexapro, Placebo | Takeda | Treatment Outcome | 12/13 | 12/13 | | |
2004-000990-78: A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Symptoms. |
|
|
| Completed | 3 | 48 | Europe | Cipralex, Lu 26-054, Cipralex, Cipralex | H. Lundbeck A/S, H. Lundbeck A/S, Lundbeck Austria GmbH | Depressive symptoms in post myocardial infarction patients | | 06/05 | | |
NCT02272517 / 2014-000231-16: Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder |
|
|
| Completed | 3 | 101 | Europe, RoW | Vortioxetine 10-20 mg, Brintellix®, Lu AA21004, Escitalopram 10-20 mg | H. Lundbeck A/S | Major Depressive Disorder | 03/16 | 03/16 | | |
NCT02191397: Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder |
|
|
| Completed | 3 | 534 | RoW | Bupropion, Bupropion Matching Placebo, Escitalopram, Escitalopram Matching Placebo | GlaxoSmithKline | Depressive Disorder, Major | 10/16 | 10/16 | | |
| Completed | 3 | 2944 | Canada, US, Europe, RoW | OPC-34712, Escitalopram, Lexapro, Fluoxetine, Prozac, Paroxetine CR, Paxil CR, Sertraline, Zoloft, Duloxetine, Cymbalta, Venlafaxine XR, Effexor XR | Otsuka Pharmaceutical Development & Commercialization, Inc. | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | 04/17 | 05/17 | | |
|
TRANSFORM-2, NCT02418585 / 2014-004585-22: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 236 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 06/17 | 11/17 | | |
|
TRANSFORM-3, NCT02422186 / 2014-004588-19: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 139 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 08/17 | 08/17 | | |
|
| Completed | 3 | 802 | Europe, US, RoW | Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 10/17 | 10/17 | | |
| Completed | 3 | 719 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 02/18 | 02/18 | | |
TRANSFORM-1, NCT02417064 / 2014-004584-20: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 346 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 02/18 | 02/18 | | |
|
NCT00958633: Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. |
|
|
| Completed | 3 | 178 | Canada | Escitalopram, Lexapro/Cipralex, Wellbutrin XL, Wellbutrin | University of British Columbia, Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, Lundbeck Canada Inc., Lupin Limited | Bipolar I Disorder | 03/20 | 05/20 | | |
NCT03434041: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 252 | US, RoW | Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 04/21 | 04/21 | | |
NCT03852160: A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression |
|
|
| Withdrawn | 3 | 0 | NA | Esketamine 28 mg, JNJ-54135419, Esketamine 56 mg, Esketamine 84 mg, Placebo, Escitalopram, Sertraline, Duloxetine, Mirtazapine, Agomelatine, Bupropion, Trazodone Prolonged Release | Janssen-Cilag International NV | Depressive Disorder, Treatment-Resistant | 07/21 | 07/21 | | |
NCT04476030: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 440 | US | SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine | Biogen | Depressive Disorder, Major | 10/21 | 12/21 | | |
|
|
| Terminated | 3 | 111 | RoW | Escitalopram 10mg, LABCAT TCJUSS, LABCAT TCJUSS Placebo, Escitalopram Placebo | Laboratório Catarinense SA, Universidade Federal do Ceara, Financiadora de Estudos e Projetos | Depression | 06/22 | 06/22 | | |
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 1149 | US | Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 07/22 | 07/22 | | |
NCT00121069: Study of Escitalopram in the Treatment of Specific Phobia |
|
|
| Completed | 2/3 | 12 | US | Escitalopram | Connor, Kathryn M., M.D., Forest Laboratories | Phobic Disorders | | 09/04 | | |
NCT00215228: Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression |
|
|
| Completed | 2/3 | 26 | US | duloxetine vs. escitalopram | Duke University, Forest Laboratories | Major Depressive Disorder | | 08/07 | | |
NCT00481325: Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder |
|
|
| Completed | 2/3 | 260 | US | pexacerfont, (BMS-562086), escitalopram, placebo | Bristol-Myers Squibb | Generalized Anxiety Disorder | 03/08 | 03/08 | | |
| Terminated | 2/3 | 18 | Europe | escitalopram, pindolol, escitalopram/Cipralex, pindolol/Viskene, escitalopram | Markus KOSEL, University Hospital, Geneva, University of Lausanne Hospitals, University Hospital, Basel, Switzerland, H. Lundbeck A/S | Unipolar Depression | 04/13 | 06/13 | | |
